Journals / ANKEM Dergisi / 2011 / Cilt: 25 - Sayı: 1

Thiomersal and autism

Tiomersal ve otizm

Pages
62–69
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Indeed in 1999 after the end of thiomersal use as a preservative in vaccines in the United States, it was showed that autism did not decrease in children and controversially gradually increased and it was concluded that autism occurs as a result of different causes.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Vaccines which were developed for the purpose of protection from infectious diseases, have been criticized in terms of both themselves and their additives.
📊
Key Findings & Data:Geier and Geier, the leading researchers who relate thiomersal to autism, starting from 2003 until today, have suggested insistently the existence of this relationship in about twenty articles based on the data of the United States Vaccine Adverse Reporting System.
💡
Conclusion & Impact:Indeed in 1999 after the end of thiomersal use as a preservative in vaccines in the United States, it was showed that autism did not decrease in children and controversially gradually increased and it was concluded that autism occurs as a result of different causes.
🔬Design:Research Article
📍Scope:2003 Verileri
⚙️Variables:Domain Parameters

Abstract

Vaccines which were developed for the purpose of protection from infectious diseases, have been criticized in terms of both themselves and their additives. Because of these critism, some of which is based on scientific research and through media in various sectors of society, various problems have been experienced in the use of vaccines. Despite of all these criticisms, more effective and harmless methods than vaccines for the prevention of communicable diseases could not be developed. Thiomersal, used in multidose vaccines in order to prevent contamination, has been taken under the lens for years in terms of its side effects. Thiomersal, especially in children, has caused controversy in terms of autism. Geier and Geier, the leading researchers who relate thiomersal to autism, starting from 2003 until today, have suggested insistently the existence of this relationship in about twenty articles based on the data of the United States Vaccine Adverse Reporting System. On the other hand, by many researchers, it has been stated that the use of epidemiological studies will be inadequate to reach an accurate conclusion and will lead to inaccurate results. Indeed in 1999 after the end of thiomersal use as a preservative in vaccines in the United States, it was showed that autism did not decrease in children and controversially gradually increased and it was concluded that autism occurs as a result of different causes. In this interview, thiomersal (and its ingredient mercury) used as a preservative in vaccines, has been examined in accompaniance of literature in terms of the autism it may cause.

Özet

Bulaşıcı hastalıklardan korunma amacıyla geliştirilen aşılar içerdikleri katkı maddeleri açısından yıllarca eleştiri konusu olmuştur. Bir kısmı medya aracılığı ile toplumun çeşitli kesimlerinde, bir kısmı da bilimsel araştırmalara dayanan bu eleştiriler nedeniyle aşıların kullanımında çeşitli sıkıntılar yaşanmaktadır. Tüm bunlara rağmen bulaşıcı hastalıkların önlenmesinde aşılardan daha etkin ve zararsız bir yöntem de henüz geliştirilememiştir. Multidoz aşıların içerisinde, onların kontamine olmasını önlemek amacıyla kullanılan tiomersal, oluşturabileceği yan etkileri açısından bilim çevrelerinde yıllardır mercek altına alınmaktadır. Tiomersal, özellikle çocuklarda oluşturabileceği otizm açısından tartışmalara neden olmuştur. Tiomersal ile otizm arasında ilişki kuran araştırıcıların öncüleri olan Geier ve Geier, 2003 yılından başlayarak günümüze kadar ABD’deki “Aşı Yan Etki Raporlama Sistemi” [Vaccine Adverse Events Reporting System (VAERS)] verilerine dayanarak yayınladıkları yirmiye yakın makalenin hepsinde ısrarla bu ilişkinin varlığını öne sürmüşlerdir. Diğer yandan bir çok araştırıcı tarafından, bu sisteme ait verilerin kullanılması ile yapılacak epidemiyolojik çalışmaların doğru bir sonuca ulaşılabilmesi açısından yetersiz olacağı ve yanlış sonuçlara yol açacağı belirtilmiştir. Nitekim 1999 yılında ABD’de aşılarda koruyucu olarak tiomersal kullanımına son verilmesinden sonra çocuklarda azalması beklenen otizmin azalmadığı ve giderek arttığı yapılan çalışmalarda gösterilmiş ve otizmin farklı nedenlerle oluştuğu sonucuna varılmıştır. Bu derlemede aşıların içerisinde koruyucu olarak kullanılan tiomersal ve içerdiği cıva, oluşturabileceği otizm açısından literatür eşliğinde incelenmiştir.

🔖

Cite This Article

GÜDÜCÜOĞLU, H., BERKTAŞ, M., YAMAN, G. (2011). Thiomersal and autism. ANKEM Dergisi, Cilt: 25 - Sayı: 1, 62–69. https://ajindex.com/articles/159237

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal association, Pediatrics 2004
  2. 114(3):584-91. http://dx.doi.org/10.1542/peds.2003-1177-L PMid:15342825 2. Aschner M, Ceccatelli S. Are neuropathological conditions relevant to ethylmercury exposure? Neurotox Res 2010
  3. 18(1):59-68. http://dx.doi.org/10.1007/s12640-009-9113-2 PMid:19756911 3. Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines, Pediatrics 2001
  4. 107(5):1147-54. http://dx.doi.org/10.1542/peds.107.5.1147 PMid:11331700 4. Berman RF, Pessah IN, Mouton PR, Mav D, Harry J. Low-level neonatal thimerosal exposure: further evaluation of altered neurotoxic potential in SJL mice, Toxicol Sci 2008
  5. 101(2):294-309. http://dx.doi.org/10.1093/toxsci/kfm265 PMid:17977901 5. Bernard S, Enayati A, Roger H, Binstock T, Redwood L. The role of mercury in the pathogenesis of autism, Mol Psychiatry 2002
  6. (7 Suppl 2):42-3. http://dx.doi.org/10.1038/sj.mp.4001177 PMid:12142947 6. Bigham M, Copes R. Thiomersal in vaccines: balancing the risk of adverse effects with the risk of vaccine-preventable disease, Drug Saf 2005
  7. 28(2):89-101. http://dx.doi.org/10.2165/00002018-200528020-00001 PMid:15691220 7. Burbacher TM, Shen DD, Liberato N, Grant KS, Cemichiari E, Clarkson T. Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal, Environ Health Perspect 2005
  8. 113(8):1015-21. http://dx.doi.org/10.1289/ehp.7712 PMid:16079072 PMCid:1280342 8. Centers for Disease Control and Prevention (CDC). Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service, Morb Mortal Wkly Rep 1999
  9. 48(26):563-5. PMid:10418806 9. Centers for Disease Control and Prevention (CDC).National and state-specific pregnancy rates among adolescents-United States, 1995-1997, Morb Mortal Wkly Rep 2000
  10. 49(27):605-11. PMid:10914926 10. Centers for Disease Control and Prevention (CDC). Impact of the 1999 AAP/USPHS joint statement on thimerosal in vaccines on infant hepatitis B vaccination practices, Morb Mortal Wkly Rep 2001
  11. 50(6):94-7. PMid:11263794 11. Clements CJ. The evidence for the safety of thiomersal in newborn and infant vaccines, Vaccine 2004
  12. 22(15-16):1854-61. http://dx.doi.org/10.1016/j.vaccine.2003.11.017 PMid:15121295 12. Eldred BE, Dean AJ, McGuire TM, Nash AL. Vacci